Back to News
Market Impact: 0.2
Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Seres Therapeutics reported a quarterly loss of $1.06 per share, narrower than the Zacks Consensus Estimate of a $1.34 loss. That compares with earnings of $0.94 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
MCRB0.40
More News
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- What Democrats’ midterm sweep means for your investments